Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ST 266

Next Previous
Drug Profile

ST 266

Alternative Names: ST-266

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Noveome
  • Developer Noveome; Walter Reed Army Institute of Research
  • Class Anti-inflammatories; Antiallergics; Antiglaucomas; Cytokines; Eye disorder therapies; Growth factors; Intercellular signalling peptides and proteins; Neuroprotectants; Proteins; Small molecules
  • Mechanism of Action Bone development modulators; Neuron modulators; Paracrine communication modulators; Proto oncogene protein c akt modulators; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Necrotising enterocolitis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic conjunctivitis; Corneal disorders; Periodontitis
  • Phase I/II Necrotising enterocolitis
  • Phase I Cytokine release syndrome
  • Research Traumatic brain injuries
  • No development reported Brain injuries; Burns; Dry eyes; Emphysema; Gingivitis; Ocular hypertension; Optic neuritis

Most Recent Events

  • 02 Apr 2024 Phase-I/II clinical trials in Necrotising enterocolitis (In infants, In neonates) in USA (unspecified route) (NCT06315738)
  • 28 May 2023 No recent reports of development identified for preclinical development in Emphysema in USA
  • 28 May 2023 No recent reports of development identified for preclinical development in Necrotising enterocolitis in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top